On March 23, 2023, three prostate cancer patients, Robert Sachs, Clare Love and Eric Sawyer, filed an administrative appeal of the NIH decision to reject petition that HHS use Federal rights in patents on Xtandi to address pricing discrimination against… Continue Reading
NIH-rejection-Xtandi-marchin-12march2023 This is an appalling decision. The worst is this quote: “practical application is evidenced by the “manufacture, practice, and operation” of the invention and the invention’s “availability to and use by the public….” This is what 35 USC 201(f)… Continue Reading
I’m in a two day meeting in Geneva on new approaches to affordable monoclonal antibodies (mAbs), and it made me think of a provision found in some bills that have been proposed or introduced in the U.S. Congress to force… Continue Reading
KEI has shared this analysis of the WIPO negotiations on a broadcasting treaty with negotiators. WIPO-Broadcast-Treaty-Analysis-28Feb2023 Brief update 1: The WIPO negotiations on a broadcasting treaty began in 1997. This week, the broadcasters hope to finally get an SCCR node… Continue Reading
On February 14, 2023, USDOJ filed a Statement of Interest of the United States, in the patent dispute between Arbutus Biopharma, Genevant Sciences, and Moderna. A copy of the filing is here: arbutus.moderna.USG.statementofinterest This is an important, and while not… Continue Reading
WHO-zero-draft-pandemic-treaty-1Feb2023 There is much to like in this draft on topics such as intellectual property rights, transparency, benefit sharing and equity. Easy to see why big drug companies have been alarmed at the direction of the WHO work on this.… Continue Reading
USTR-Special301-2023-KEI-coments KEI comments on the 2023 USTR Special 301 Review Comments provided by James Love, on behalf of Knowledge Ecology International 110 Maryland Avenue, NE, Washington, DC 20002 Telephone: +1.202.332.2670 James.Love@KEIOnline.Org In response to Federal Register Notice: Docket Number USTR-2022-0016… Continue Reading
NIH has sent a letter, dated Dec 1, to Robert Sachs and Clare Love, regarding the longstanding petition to HHS to use the federal government’s rights in the patented inventions for enzalutamide, marketed by Astellas in the USA at prices 3 to… Continue Reading
Attached is a letter from 19 groups asking HHS Secretary Xavier Becerra to take action on the request that HHS use the federal government rights in patents on the prostate drug enzalutamide, marketed by Astellas under the brand name Xtandi.… Continue Reading